Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Dalton

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Project Inform Perspective|December 3, 2008
Isentress gets another good gradePaul Dalton
Project Inform Perspective|December 3, 2008
Heat stable formulation of Norvir appears likelyPaul Dalton
Project Inform Perspective|March 3, 2009
Update to the Federal Guidelines for treating HIV disease in adults and adolescentsPaul Dalton
Project Inform Perspective|December 3, 2008
Abacavir controversy continues to brewPaul Dalton
Project Inform Perspective|December 4, 2008
Two new NNRTIs enter the pipelinePaul Dalton
Project Inform Perspective|December 3, 2008
Apricitabine continues to show good resultsPaul Dalton
Project Inform Perspective|December 4, 2008
Immune based therapy offers intriguing possibilityPaul Dalton
Project Inform Perspective|December 3, 2008
Anthony Fauci lends support to focus on curePaul Dalton
Project Inform Perspective|December 3, 2008
TRIO study's novel combination shows promisePaul Dalton
Project Inform Perspective|December 3, 2008
Mexican study may forecast advances naívesPaul Dalton
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Project Inform Perspective|December 3, 2008
Isentress gets another good gradePaul Dalton
Project Inform Perspective|December 3, 2008
Heat stable formulation of Norvir appears likelyPaul Dalton
Project Inform Perspective|March 3, 2009
Update to the Federal Guidelines for treating HIV disease in adults and adolescentsPaul Dalton
Project Inform Perspective|December 3, 2008
Abacavir controversy continues to brewPaul Dalton
Project Inform Perspective|December 4, 2008
Two new NNRTIs enter the pipelinePaul Dalton
Project Inform Perspective|December 3, 2008
Apricitabine continues to show good resultsPaul Dalton
Project Inform Perspective|December 4, 2008
Immune based therapy offers intriguing possibilityPaul Dalton
Project Inform Perspective|December 3, 2008
Anthony Fauci lends support to focus on curePaul Dalton
Project Inform Perspective|December 3, 2008
TRIO study's novel combination shows promisePaul Dalton
Project Inform Perspective|December 3, 2008
Mexican study may forecast advances naívesPaul Dalton
Pageof 2